Opexa Therapeutics (ACER) Downgraded to Sell at ValuEngine
ValuEngine downgraded shares of Opexa Therapeutics (NASDAQ:ACER) from a hold rating to a sell rating in a research report released on Friday.
Opexa Therapeutics (ACER) traded up $0.16 during midday trading on Friday, reaching $16.79. 3,682 shares of the company’s stock were exchanged, compared to its average volume of 6,620. Opexa Therapeutics has a 12 month low of $5.69 and a 12 month high of $22.63.
Opexa Therapeutics (NASDAQ:ACER) last released its earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.09) EPS for the quarter.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/12/02/opexa-therapeutics-acer-downgraded-to-sell-at-valuengine.html.
Opexa Therapeutics Company Profile
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
Receive News & Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.